Septerna, Inc.

NASDAQ:SEPN

Biotechnology

Healthcare
$39.45 -2.04%

-$0.73 today

Market cap
$1.88B
Beta
2.38
P/E (TTM)
-43.6
EPS (TTM)
-$0.81
52W Low $9.96High $37.32

Volume 0.30M

Average 0.32M

SEPN EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Septerna, Inc.NASDAQ: SEPN

EBITDA · Q3 FY2026 · quarter ended Sep 2026

EBITDA remains negative

Q3 FY2026 EBITDA was -$27.23M, compared with -$9.49M a year earlier. Trailing-twelve-month EBITDA was -$57.07M.

Context

  • EBITDA amounted to 102.9% of revenue in FY2025, down 6492.0 pp from a year earlier.
  • EBITDA grew in size in 1 of the last 2 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 7 analysts of -$36.13M (+23.6%) for the fiscal year ending Dec 2026, a slowdown from the +33.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
-$27.23M-134.0% QoQ
Last fiscal yearDec 2025
-$47.26M+33.3% YoY
LTMSep 2026
-$57.07M+24.4% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-187.1%+1.3%+188.4 pp
1 year+33.3%+23.6%-9.8 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(47.26M) USD
Year-over-year change
+33.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How SEPN compares with its peers on the latest reported figures

  • SEPN's LTM Sep 2026 EBITDA of -$57.07M is the 3rd highest of the 7 companies compared; the peer median is -$134.05M.
  • Its year-over-year change of +24.4% is the 3rd highest of 6, against a peer median of -19.8%.
  • EBITDA amounts to 59.3% of revenue for SEPN, versus a peer median of 299.8%.
SEPN Competitors Peer median
EBITDA for SEPN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VTVTvTv Therapeutics Inc.LTM Mar 2026-$715K +96.9%—1.9%
BMEABiomea Fusion, Inc.LTM Mar 2026-$46.12M +63.6%——
SEPNSepterna, Inc.LTM Sep 2026-$57.07M +24.4%—59.3%
MAZEMaze Therapeutics, Inc.LTM Mar 2026-$119.51M -312.9%—597.6%
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026-$148.59M -85.2%——
KLRAKailera Therapeutics, Inc.FY2025-$158.03M ———
GPCRStructure Therapeutics Inc.LTM Jun 2026-$212.44M -19.8%——
Peer median (excluding SEPN) -$134.05M-19.8%—299.8%

Competitors are the stored peer set for SEPN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue151K1.08M45.95M
Cost of Revenue000
Gross Profit151K1.08M45.95M
Gross Margin100.0%100.0%100.0%
Research & Development35.98M65.34M97.58M
Selling, General & Admin9.72M16.56M29.16M
Operating Expenses(1.92M)81.9M126.75M
Depreciation & Amortization848K1.4M1.6M
EBITDA(44.7M)(70.9M)(47.26M)
EBITDA Margin-29604.0%-6594.9%-102.9%
Operating Income2.08M(80.82M)(80.8M)
Operating Margin1374.2%-7518.4%-175.8%
Interest Income2.79M8.62M19.53M
Interest Expense000
Other Income / Expenses2.8M8.53M31.93M
Income Before Tax4.87M(72.3M)(48.87M)
Pre-Tax Margin3225.8%-6725.2%-106.3%
Income Tax Expense691K(498K)12K
Net Income4.18M(71.8M)(48.88M)
Net Margin2768.2%-6678.9%-106.4%
EPS (Basic)0.03(1.93)(1.10)
EPS (Diluted)0.03(1.93)(1.10)
Weighted Avg Shares19.5M37.19M44.26M
Weighted Avg Shares (Diluted)19.5M37.19M44.26M

Septerna, Inc.

NASDAQ:SEPN

Intrinsic Alpha fair value

Locked

Current Price

$39.45

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.